Eyebright Medical Technology Beijing Co Ltd (688050) — Capital Reinvestment Ratio

Latest as of September 2025: 0.28x

Eyebright Medical Technology Beijing Co Ltd (688050) has a Capital Reinvestment Ratio of 0.28x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥76.92 Million) in capital expenditures (CN¥21.37 Million). See net asset quality index of Eyebright Medical Technology Beijing Co to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

0.28x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥76.92 Million
CNY

Capital Expenditures

CN¥21.37 Million
CNY

Data as of

Sep 2025
Most recent filing

Eyebright Medical Technology Beijing Co Ltd Capital Reinvestment Ratio (2017–2025)

This chart tracks Eyebright Medical Technology Beijing Co Ltd's Capital Reinvestment Ratio across 9 annual periods. Check Eyebright Medical Technology Beijing Co investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for Eyebright Medical Technology Beijing Co Ltd (2017–2025)

Year-by-year Capital Reinvestment Ratio for Eyebright Medical Technology Beijing Co Ltd from 2017 to 2025. For live market cap and broader valuation context, see 688050 company net worth.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2025 0.33x CN¥369.15 Million CN¥123.14 Million ▼ -64.8%
2024 0.95x CN¥347.75 Million CN¥329.48 Million ▼ -42.1%
2023 1.64x CN¥226.27 Million CN¥370.34 Million ▲ +51.1%
2022 1.08x CN¥250.13 Million CN¥271.03 Million ▼ -23.6%
2021 1.42x CN¥219.30 Million CN¥311.22 Million ▲ +47.4%
2020 0.96x CN¥123.35 Million CN¥118.73 Million ▼ -65.7%
2019 2.80x CN¥50.49 Million CN¥141.61 Million ▲ +24.3%
2018 2.26x CN¥31.82 Million CN¥71.81 Million ▼ -70.3%
2017 7.60x CN¥4.15 Million CN¥31.53 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow